EHA Meeting 2026
At this year
Kite Publications:
| Title | Author List | Presentation information |
|---|---|---|
|
A Phase 1 Study of KITE-753 in Patients with R/R B |
Saurabh Dahiya, Matthew Ulrickson, Jean Yared, Patrick M. Reagan, Timothy Voorhees, Andre Goy, Cameron J. Turtle, Lizama… |
Poster Session 2: Saturday, June 13, (18:45 |
|
Anitocabtagene Autoleucel Clinical Trial Manufacturing Experience in Patients with R/R or Newly Diagnosed MM |
Krina Patel, Clare Spooner, Monique Giordana, Taryn Shuler, David Myers, Maria |
Abstract Code: PB3252 |
|
Axicabtagene Ciloleucel as Second-line Treatment in Patients with Late-relapsed LBCL: Interim Analysis of the LATE-R Clinical Trial from the Spanish Lymphoma Group GELTAMO |
Mariana Bastos-Oreiro, Armando L+ |
Poster Session 1: Friday, June 12 (18:45 |
|
Axicabtagene Ciloleucel for the Treatment of R/R DLBCL in Brazil: The Impact of CAR T-cell Therapy Wait Time and Treatment Sequencing |
Jo+ |
Abstract Code: PB3720 |
|
Biologic Correlates of Long |
Sabina Adhikary, Kelly Speth, Colleen Schweitzer, Rhine Shen, Ioana Kloos, Marie Jos+ |
Poster Session 2: Saturday, June 13 (18:45 |
|
CAR T Cell Therapy in Clinical Routine: Quantification of Real-World Hospital Resource Use Across CAR T Care Pathway in Germany |
Katja Hesse, Isabell Kaufhold, Markus Finzsch, Florian Kron |
Poster Session 1: Friday, June 12 (18:45 |
|
Clinical and Economic Outcomes by Risk Group Among First-Line Patients with LBCL in the United States (US)-SEER-Medicare Data Analysis |
Yi Lin, Liana Nikolaenko, Elyse Swallow, Madhu Palivela, Jinlin Song, Markqayne Ray, Sakshi Sethi, David Cobley, Matthew… |
Abstract Code: PB3775 |
|
Cost-Effectiveness Analysis of Brexucabtagene Autoleucel in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Singapore |
Esther Chan, Nurul A Abdul Halim, Tza Kai Diong, Emma New, Briana Tan, Francesca L.W.I. Lim |
Poster Session 2: Saturday, June 13 (18:45 |
|
Cost-Effectiveness of Axicabtagene Ciloleucel for Treating Taiwanese Patients with R/R DLBCL and High-Grade B-cell Lymphoma After First-Line Treatment |
Bor-Sheng Ko, Wen-Wen Yang, Yu-Chiao Wang, Diong Tza-Kai, Kuan-Der Lee, Raoh-Fang Pwu |
Poster Session 2: Saturday, June 13 (18:45 |
|
Cost-Effectiveness of Axicabtagene Ciloleucel in Taiwanese Patients with R/R DLBCL and Primary Mediastinal B-Cell Lymphoma After Two Lines of Systemic Therapy |
Kuan-Der Lee, Yu-Chiao Wang, Wen-Wen Yang, Diong Tza-Kai, Bor-Sheng Ko, Raoh-Fang Pwu |
Poster Session 1: Friday, June 12 (18:45 |
|
Exploring Global Variation in CAR T-Cell Therapy Practice Patterns for LBCL: Quantitative Research Findings |
Samuel Yamshon, Gloria Ines Iacoboni Garcia-Calvo, David Qualls, Ajay Major, Lizamarie Bachier-Rodriguez, Anna Maria Sur… |
Abstract Code: PB3712 |
|
Follow-Up Time |
Michael Leisch, Thomas Melchardt, Guido Ghilardi, Caroline Arber, Ulrich J+ |
Poster Session 2: Saturday, June 13 (18:45 |
|
International Expert Consensus on Real-World CAR T-Cell Eligibility in LBCLs: An e-Delphi Study |
Catherine Thieblemont, Isabelle Fleury, Mazyar Shadman, Tobias A.W. Holderried, Graham Collins |
Poster Session 1: Friday, June 12 (18:45 |
|
Real-World Treatment Patterns and Survival Outcomes in Patients With Newly Diagnosed High-Risk LBCL |
Ran Reshef, Javier Munoz, Babatunde Adedokun, Qian Huang, Hil Hsu, Nan Liu, Madhu Palivela, Zhen-Huan Hu, Liana Nikolaen… |
Poster Session 1: Friday, June 12 (18:45 |
CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; (R/R) DLBCL, (relapse/refractory) diffuse large B-cell lymphoma.